Southeastern Michigan Parkinson's Disease Program

密歇根州东南部帕金森病项目

• 批准号: 6666859
• 负责人: PETER A LEWITT
• 金额: $ 7.71万
• 依托单位: WILLIAM BEAUMONT HOSPITAL RESEARCH INST
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6666859
• 关键词: Parkinson's disease; brain disorder chemotherapy; clinical research; cooperative study; disease /disorder onset; drug screening /evaluation; human subject; human therapy evaluation; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): This application responds to RFA-NS-02-010 ("Parkinson Disease Neuroprotection Trial: Clinical Centers"). The Southeastern Michigan Parkinson's Disease Program describes the research experience, facilities, and operational capabilities for collaborative sites that will work together closely: the William Beaumont Hospital System, the Clinical Neuroscience Center (CNC), a Parkinson's disease (PD) research and treatment program in Southfield, and the PD clinics at the Wayne State University School of Medicine (WSU SOM) campus in Detroit. We propose to participate in a nationwide effort for recruiting and conducting randomized, double blind clinical trials of neuroprotection for PD. The CNC, designated by the National Parkinson Foundation as Michigan's Center of Excellence, has developed the State's largest PD patient base and referral network. For almost 20 years, the CNC has been one of the nation's leading sites for conducting Phase 1 through IV clinical research in PD. The CNC's extensive affiliations with the region's PD patient community as well as with health providers in Michigan, Ohio, and southwestern Ontario should maximize opportunities for recruiting de novo PD patients. The two sites will enhance the diversity of study participants, especially with the WSU SOM services to a large inner city population and a major Veterans Administration Medical Center.The CNC's extensive experience in PD drug research has involved clinical trials (including several neuroprotection studies) sponsored by the pharmaceutical industry, the NIH, and the Parkinson Study Group. The Principal Investigator is enthusiastic to participate in the multi-site collaborative program and can offer a leadership role in the choice and coordination of studies.This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection.

描述（由申请人提供）：本申请响应RFA-NS-02-010（“帕金森病神经保护试验：临床中心”）。密歇根州东南部帕金森病项目描述了将密切合作的协作站点的研究经验、设施和运营能力：威廉博蒙医院系统、临床神经科学中心（CNC）、南菲尔德的帕金森病（PD）研究和治疗项目，以及底特律州立大学韦恩医学院（WSU SOM）的PD诊所。我们建议参与全国范围内的努力，招募和进行随机，双盲临床试验的神经保护PD。CNC被国家帕金森基金会指定为密歇根州的卓越中心，已经开发了该州最大的PD患者基础和转诊网络。近20年来，CNC一直是全国领先的PD 1期至IV期临床研究中心之一。CNC与该地区的PD患者社区以及密歇根州、俄亥俄州和安大略西南部的医疗服务提供者的广泛联系应该最大限度地增加招募原发PD患者的机会。这两个研究中心将增强研究参与者的多样性，特别是WSU SOM服务于大型内城人口和主要的退伍军人管理局医疗中心。CNC在PD药物研究方面的丰富经验涉及制药行业，NIH和帕金森研究组赞助的临床试验（包括几项神经保护研究）。主要研究者热衷于参与多中心合作项目，并能在研究的选择和协调方面发挥领导作用。本申请还讨论了三种药理学药物的概念，这些药物可在试点研究中进行研究，如果有希望，可在多中心临床试验中评估神经保护作用。